Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol

Cruz,Pamela; Torres,Cristian; Ramírez,María E.; Epuñán,María J.; Valladares,Luis E.; Sierralta,Walter D.

doi:10.3892/etm_00000084

Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol

Authors:
- Pamela Cruz
- Cristian Torres
- María E. Ramírez
- María J. Epuñán
- Luis E. Valladares
- Walter D. Sierralta
View Affiliations

Affiliations: Laboratorio de Nutrición y Regulación Metabólica, INTA-Universidad de Chile, Santiago 7830489, Chile
Published online on: May 1, 2010 https://doi.org/10.3892/etm_00000084
Pages: 531-536

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify the possible mechanisms by which certain estradiol receptor (ER)-positive mammary tumor cells remain resistant to treatment with anti-estrogens or inhibitors of local estradiol (E2) production. To this end, we compared the proliferative effects on mammary cancer cells of the novel selective ER modulator 27-hydroxycholesterol (27OHC) to those of E2, and evaluated their inhibition by ICI 182,780 (ICI). Analysis of the effects on the cell cycle of 27OHC and E2 in the absence or presence of ICI was conducted. In ER-positive mammary tumor cells, we detected the blocking of 27OHC proliferation-stimulatory activity by simvastatin, as well as the inhibition of E2-stimulated proliferation by an α-fetoprotein-derived cyclic nonapeptide. The effects reported herein may be extrapolated to infiltrating mammary cancer, where the activity of local macrophages may stimulate tumor growth. We suggest that increased breast cancer growth in obese patients may be related to increased 27OHC circulatory levels.

View Figures

View References

1.	Russo IH and Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 3:49–61. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Conzen SD: Nuclear receptors and breast cancer. Mol Endocrinol. 22:2215–2228. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Fox EM, Andrade J and Shupnik MA: Novel actions of estrogen to promote proliferation integration of cytoplasmic and nuclear pathways. Steroids. 74:622–627. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA and Katzenellenbogen BS: Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol. 22:2116–2127. 2008. View Article : Google Scholar : PubMed/NCBI
5.	He J, Cheng Q and Xie W: Minireview: nuclear receptor-controlled steroid hormone synthesis and metabolism. Mol Endocrinol. 24:11–21. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Sasano H, Suzuki T, Nakata T and Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer. 13:129–136. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Arpino G, Weichmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 29:217–233. 2008. View Article : Google Scholar
8.	Hall JM and McDonnell DP: Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv. 5:343–357. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Shelly W, Draper MW, Krishnan V, Wong M and Jaffe RB: Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 63:163–181. 2008.PubMed/NCBI
10.	Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW and Mangelsdorf DJ: 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogens. Nature Med. 13:1185–1192. 2007. View Article : Google Scholar : PubMed/NCBI
11.	DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ and McDonnell DP: 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 22:65–77. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Brown AJ and Jessup W: Oxysterols and atherosclerosis. Atherosclerosis. 142:1–28. 1999. View Article : Google Scholar
13.	Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, Miyazaki T and Matsuzaki Y: Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res. 39:149–156. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Babiker A, Dzeletovic S, Wiklund B, Pettersson N, Salonen J, Nyyssönen K, Eriksson M, Diczfalusy U and Björkhem I: Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest. 65:365–375. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Hultén LM, Lindmark H, Diczfalusy U, Björkhem I, Ottosson M, Liu Y, Bondjers G and Wiklund O: Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J Clin Invest. 97:461–468. 1996.PubMed/NCBI
16.	Olkkonen VM and Hynynen R: Interactions of oxysterols with membranes and proteins. Mol Aspects Med. 30:123–133. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Lemaire-Ewing S, Prunet C, Montange T, Vejux A, Berthier A, Bessede G, Corcos L, Gambert P, Neel D and Lizard G: Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol Toxicol. 21:97–114. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Riendeau V and Garenc C: Effect of 27-hydroxycholesterol on survival and death of human macrophages and vascular smooth muscle cells. Free Radic Res. 43:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Li T, Chen W and Chiang JY: PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 48:373–384. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Oyama T, Miyashita Y, Kinoshita K, Watanabe H, Shirai K and Yagima T: Effect of deposited lipids in atheromatous lesions on the migration of vascular smooth muscle cells. J Atheroscler Thromb. 9:109–113. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Kummerow FA, Mahfouz MM, Zhou Q and Cook LS: 27-Hydroxycholesterol causes remodeling in endothelial cell membrane lipid composition comparable to remodeling in the failed vein grafts of CABG patients. Life Sci. 78:958–963. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Lange Y, Ory DS, Ye J, Lanier MH, Hsu FF and Steck TL: Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem. 283:1445–1455. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Sierralta WD, Epuñán MJ, Reyes JM, Valladares LE, Andersen TT, Bennett JA, Jacobson HI and Pino AM: A peptide derived from α-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture. Oncol Rep. 19:229–235. 2008.
24.	Sierralta WD, Epuñán MJ, Reyes JM, Valladares LE and Pino AM: A cyclic nonapeptide derived from alpha-fetoprotein inhibits the estradiol-induced proliferation of mammary tumor cells in culture through the modulation of p21. Adv Exp Med Biol. 617:463–468. 2008. View Article : Google Scholar
25.	Torres C, Antileo E, Epuñán MJ, Pino AM, Valladares LE and Sierralta WD: A cyclic peptide derived from α-fetoprotein inhibits the proliferative effects of the epidermal growth factor and estradiol in MCF7 cells. Oncol Rep. 19:1597–1603. 2008.
26.	Torres CG, Pino AM and Sierralta WD: A cyclized peptide derived from α-fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep. 21:1397–1404. 2009.
27.	DuSell CD and McDonnell DP: 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends Pharmacol Sci. 29:510–514. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Lange Y, Steck TL, Ye J, Lanier MH, Molugu V and Ory D: Regulation of fibroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. J Lipid Res. 50:1881–1888. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Steele RJ, Eremin O, Brown M and Hawkins RA: A high macrophage content in human breast cancer is not associated with favourable prognostic factors. Br J Surg. 71:456–458. 1984. View Article : Google Scholar : PubMed/NCBI
30.	Javitt NB: 25R,26-Hydroxycholesterol revisited: synthesis, metabolism and biologic roles. J Lipid Res. 43:665–670. 2002.PubMed/NCBI
31.	Chen W, Chen G, Head DL, Mangelsdorf DJ and Russell DW: Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 5:73–79. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Vedin LL, Lewandowski SA, Parini P, Gustafsson JÅ and Steffensen KR: The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis. 30:575–579. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Culhane AC and Howlin J: Molecular profiling of breast cancer: transcriptomic studies and beyond. Cell Mol Life Sci. 64:3185–3200. 2007.PubMed/NCBI